Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Arepanrix H1N1 Vaccine in Children
NCT01035749Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2010
- Primary completion
- Sep 2010
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of recombinant influenza ha vaccine (h5n1) in influenza (4 arms), sponsored by GSK. Primary endpoints: Number of Subjects Seroconverted for HI Antibodies Against Flu A/CAL/7/09 H1N1 Strain at Day 21, Number of Subjects Seroprotected for HI Antibodies Against Flu A/CAL/7/09 H1N1 Strain at Day 21 and 1 more. Started Feb 2010; status: completed.
02
Drugs
recombinant influenza ha vaccine (h5n1)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01035749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01035749.